Novartis presents new data on targeted combination therapy at SABCS reinforcing commitment to breast cancer patients - Seite 3

Product Information
Approved indications for products vary by country and not all indications are available in every country. The product safety and efficacy profiles have not yet been established outside the approved indications. Because of the uncertainty of clinical trials, there is no guarantee that compounds will become commercially available with additional indications.

For full prescribing information, including approved indications and important safety information about marketed products, please visit
http://www.novartisoncology.com/products.jsp.

Because BKM120 (buparlisib), LEE011 (ribociclib), BYL719 (alpelisib) and LA-EP2006 are investigational compounds, the safety and efficacy profiles have not yet been fully established. Access to these investigational compounds is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. Because of the uncertainty of the outcome/results of the clinical trials, there is no guarantee that BKM120, LEE011, BYL719 and LA-EP2006 will ever be commercially available anywhere in the world.

Disclaimer
The foregoing release contains forward-looking statements that can be identified by words such as "commitment," "will," "investigational," "pipeline," "focus," "well positioned," "goal," "growing," "exploratory," "to be presented," "proposed," "yet," or similar terms, or by express or implied discussions regarding potential marketing approvals for BKM120, LEE011, BYL719 or LA-EP2006, or regarding potential new indications or labeling for Afinitor or Tykerb, or regarding potential future revenues from such products and investigational compounds. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that BKM120, LEE011, BYL719 or LA-EP2006 will be submitted or approved for sale in any market, or at any particular time. Neither can there be any guarantee that Afinitor or Tykerb will be submitted or approved for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products and investigational compounds will be commercially successful in the future. In particular, management's expectations regarding such products and investigational compounds could be affected by, among other things, the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected safety issues; unexpected manufacturing or quality issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.